CV SAFETY IN PHARMACEUTICAL DEVELOPMENT – ACADEMIC PERSPECTIVE Rob Califf MD Vice Chancellor for Clinical Research Director, Duke Translational Research.
Fecal Microbiota for Transplantation Jay E. Slater, MD FDA/CBER/OVRR/DBPAP.
Prevnar 13 for Adult Use Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM 197 Protein) Applicant: Wyeth Pharmaceuticals, Inc Nicolette deVore,
Medication Costs – Where are we going Jeanne Tuttle, R.Ph. Pharmacy Benefits Management Service, VA Central Office June 2012.
Measurements of ‘Patient Centred Care’ in Anaesthesia Dr. Sujesh Bansal Consultant Anaesthetist 18 th May 2015.
Fulfilling the Promise of Medicine Together Preparing for an IDE Application John McLane, Ph.D. COO & Vice President Clinical and Regulatory Affairs Clinquest,
Low Cost Safety Improvements Pooled Fund Study (PFS) presented by Kim Eccles, P.E. Senior Engineer, VHB.
1 Sonali Muzumdar Pharm.D., CPHIMS Informatics Pharmacist Mercy Hospital and Medical Center Comprehensive Pharmacy Services Leveraging Rules and Alerts.
1 New Strategies for Using Advanced Technology and Care Models for Safer, More Effective, More Humane Health Services No One Grows Old Saying, “Gee, I.
Nina Cohen, PhD Science Policy Officer Research & Toxicology Department
Leveraging Rules and Alerts to Improve Patient Safety and Clinical Pharmacy Services
Low Cost Safety Improvements Pooled Funds Study Increasing Retroreflectivity of STOP Signs Results